Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Efineptakin alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Efineptakin alfa overview

Efineptakin alfa (GX-I7) is under development for the treatment of human papillomavirus infections, solid tumor including high grade glioma, recurrent glioblastoma and melanoma, triple negative breast cancer, high grade gliomas such as glioblastoma multiforme, cervical intraepithelial neoplasia (CIN), triple-negative breast cancer, colorectal cancer, anal, bile duct cancer, rectal, deuodenal cancer, small-cell lung cancer, ovarian cancer, esophageal adenocarcinoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, squamous cell carcinoma, recurrent head and neck cancer squamous cell carcinoma including cytologically confirmed squamous cell carcinoma of oral cavity, oropharynx, hypopharynx or larynx, idiopathic CD4 lymphocytopenia, lymphocytopenia, sezary syndrome, unspecified B-Cell lymphomas, melanoma, merkel cell carcinoma, bladder cancer, colorectal cancer, breast cancer, acute radiation syndrome, acute lymphocytic leukemia, progressive multifocal leukoencephalopathy, gliosarcoma, and coronavirus (COVID-19). It is administered as mucosal delivery, through vaginal and as intramuscular routes as an injection. The drug candidate is an IL-7 and Fc fusion protein. It is developed based on hyFc or hybrid Fc platform. It was also under development for the treatment of head and neck cancer and non-small cell lung cancer as first line therapy.

NeoImmuneTech overview

NeoImmuneTech is a drug discovery company that discovers and develops T cell-based cancer immunotherapies. The company’s lead product candidate includes Hyleukin is a T cell production factor that is used for the prevention and treatment of lymphopenia. Its is the fusion protein of engineered IL-7 and hyFc. NeoImmuneTech’s pipeline products comprise NIT-01, NIT-02, and NIT-03. The company also develops therapies for human papillomavirus (HPV) derived cancers including cervical cancer and head and neck cancer; and other cancers. It has partnership with Cellid, Inc. Genexine, BioDion, Inc. and Pohang University of Science and Technology. NeoImmuneTech is headquartered in Rockville, Maryland, The US.

For a complete picture of Efineptakin alfa’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.